I do not think any actual details have been released about what results will come out in April. My understanding is that both the 2a prevention and 2b treatment phases have a 90-day follow up before they are complete. Surely blinding could not be ended until after this 90-day milestone is achieved even though all other data has been collected. This would be by the end of March 25 for the 2a and sometime in May for the 2b study. Both arms are very small with 4 participants in the 2a and 10 in the 2b, so the processing should not take long. The initial results for the 2a were assessed by a review committee assessing the safety, dosing and if there was any positive effect late in 2024. This review committee made a statement to confirm these 2a issues were all positive, but no actual results were released. I am anticipating in April, the complete 2a results will be released and perhaps some confirmation by a safety review committee that the 2b study has proceeded without adverse effects. TI do not expect the complete 2b results will not be likely to be released until at least May 2025.
ILA Price at posting:
17.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)